tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Kalaris Therapeutics, Inc. (KLRS)
:KLRS
US Market
KLRS
Kalaris Therapeutics
Overview
Dividends
Historical Prices
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Kalaris Therapeutics (KLRS) Stock Forecast & Price Target

Compare
342 Followers
See the Price Targets and Ratings of:

KLRS Financial Forecast

KLRS Earnings Forecast

Next quarter’s earnings estimate for KLRS is -$0.10 with a range of -$0.14 to -$0.05. The previous quarter’s EPS was -$0.05. KLRS beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.56% of the time in the same period. In the last calendar year KLRS has Outperformed its overall industry.
Next quarter’s earnings estimate for KLRS is -$0.10 with a range of -$0.14 to -$0.05. The previous quarter’s EPS was -$0.05. KLRS beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.56% of the time in the same period. In the last calendar year KLRS has Outperformed its overall industry.
No data currently available

KLRS Sales Forecast

Next quarter’s sales forecast for KLRS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KLRS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.73% of the time in the same period. In the last calendar year KLRS has Preformed in-line its overall industry.
Next quarter’s sales forecast for KLRS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KLRS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.73% of the time in the same period. In the last calendar year KLRS has Preformed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on KLRS
Michael Ulz
Morgan Stanley
$0.5
Sell
-94.19%
Downside
Reiterated
08/13/24
Morgan Stanley Sticks to Its Sell Rating for AlloVir (ALVR)
Leerink Partners Analyst forecast on KLRS
Mani Foroohar
Leerink Partners
$1
Hold
-88.37%
Downside
Reiterated
08/09/24
Maintaining Hold on AlloVir Amid Financial Performance and Strategic Uncertainty
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on KLRS
Michael Ulz
Morgan Stanley
$0.5
Sell
-94.19%
Downside
Reiterated
08/13/24
Morgan Stanley Sticks to Its Sell Rating for AlloVir (ALVR)
Leerink Partners Analyst forecast on KLRS
Mani Foroohar
Leerink Partners
$1
Hold
-88.37%
Downside
Reiterated
08/09/24
Maintaining Hold on AlloVir Amid Financial Performance and Strategic Uncertainty
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

KLRS Analyst Recommendation Trends

Rating
Dec 23
Jan 24
Mar 24
May 24
Aug 24
Strong Buy
0
0
0
0
0
Buy
5
2
0
0
0
Hold
3
3
4
2
3
Sell
1
1
1
0
0
Strong Sell
2
3
3
1
1
total
11
9
8
3
4
In the current month, KLRS has received 0 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. KLRS average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.

KLRS Stock Forecast FAQ

What is KLRS’s average 12-month price target, according to analysts?
Currently, no data Available
What is KLRS’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for KLRS, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is KLRS a Buy, Sell or Hold?
      Currently, no data Available
      What is Kalaris Therapeutics, Inc.’s price target?
      Currently, no data Available
      What do analysts say about Kalaris Therapeutics, Inc.?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of KLRS?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing